Figure 5. Effect of niraparib and olaparib on tumor volume in BRCA2mut OV5311 ovarian cancer PDX model.
Tumor volume of the OV5311 model treated with niraparib or olaparib at the maximum tolerated dose. Niraparib was administered at 75 mg/kg daily for 78 days. Olaparib was administered at 75 mg/kg once daily for 44 days and then 4 mice from this group were switched to 50 mg/kg of niraparib once daily for 34 days, while the remaining 5 mice continued with 75 mg/kg of olaparib.